000150642 001__ 150642
000150642 005__ 20251017144612.0
000150642 0247_ $$2doi$$a10.1080/21641846.2025.2452143
000150642 0248_ $$2sideral$$a142748
000150642 037__ $$aART-2025-142748
000150642 041__ $$aeng
000150642 100__ $$aRomero-Elías, María
000150642 245__ $$aCOMT genotypes correlate with cancer-related fatigue in breast cancer survivors
000150642 260__ $$c2025
000150642 5060_ $$aAccess copy available to the general public$$fUnrestricted
000150642 5203_ $$aPurpose
Cancer-related fatigue (CRF) is the most common and debilitating symptom experienced by breast cancer survivors (BCS) following treatment. The influence of genetics on CRF has been sparingly investigated. This article aims to explore the suggested impact of the catechol-O-methyltransferase (COMT) Val158Met genotypes on fatigue and to evaluate the effect on other potentially related patient-reported outcomes such as quality of life, diet, pain, or emotional facets; and also the effect on objective variables such as, heart rate variability (HRV), physical activity (PA), and biomarkers (cortisol, neutrophil-to-lymphocyte ratio, and noradrenaline).
Methods
A total of 79 BCS who had finished their treatment participated in this study. COMT genotypes were categorized as Val/Val, Val/Met, or Met/Met. PERFORM questionnaire was utilized to evaluate CRF. PA and HRV were objectively measured. The rest of the variables was assessed by questionnaires.
Results
BCS with Met/Met genotype reported higher levels of fatigue (p = 0.031), compared to those with Val/Met or Val/Val genotypes. No additional associations were found with other self-reported variables, HRV, PA, or the analysed biomarkers. The findings suggest that BCS with Met/Met genotype exhibit more elevated levels of fatigue.
Conclusion
Genetic factors could have a role in the pathogenesis of CRF. BCS with the Met/Met genotype may experience higher levels of CRF. Personalized interventions based on genetic profiling could help manage CRF more effectively.
000150642 540__ $$9info:eu-repo/semantics/embargoedAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000150642 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000150642 700__ $$aGarcía-González, David
000150642 700__ $$aÁlvarez-Bustos, Alejandro
000150642 700__ $$0(orcid)0000-0001-8374-9081$$aGaratachea, Nuria$$uUniversidad de Zaragoza
000150642 700__ $$0(orcid)0000-0003-1272-0550$$aBailón, Raquel$$uUniversidad de Zaragoza
000150642 700__ $$aRamil, Elvira
000150642 700__ $$aMaximiano, Constanza
000150642 700__ $$aCebolla-Boado, Héctor
000150642 700__ $$aRuiz-Casado, Ana
000150642 7102_ $$11006$$2245$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Educación Física y Depor.
000150642 7102_ $$15008$$2800$$aUniversidad de Zaragoza$$bDpto. Ingeniería Electrón.Com.$$cÁrea Teoría Señal y Comunicac.
000150642 773__ $$g(2025), 1-14$$tFatigue: Biomedicine, Health and Behavior$$x2164-1862
000150642 8564_ $$s327817$$uhttps://zaguan.unizar.es/record/150642/files/texto_completo.pdf$$yPostprint$$zinfo:eu-repo/date/embargoEnd/2026-01-21
000150642 8564_ $$s1524806$$uhttps://zaguan.unizar.es/record/150642/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint$$zinfo:eu-repo/date/embargoEnd/2026-01-21
000150642 909CO $$ooai:zaguan.unizar.es:150642$$particulos$$pdriver
000150642 951__ $$a2025-10-17-14:17:59
000150642 980__ $$aARTICLE